compound 15e [PMID: 9544210] [4
] | TBC 1269 | TBC-1269 | TBC1269
Bimosiamose is a synthetic pan-selectin antagonist [4
] being investigated as a novel anti-inflammatory agent, primarily for controlling allergic respiratory diseases [7
], but it has also been reported to provide benefit in ischemia/reperfusion injury [1-2
]. The primary role of selectin inhibitors appears to be disruption of early events in the migration process (possibly mediated through E-selectin [3
]), thereby inhibiting their eventual extravasation from blood to the inflammed tissue.